This invention relates to a pharmaceutical formulation containing z-butylidenephthalide and a polymer, e.g., a polyanhydride. Also disclosed is use of this formulation to treat tumor.
A series of bisbenzaldehydes and structurally related analogs, conveniently synthesized via microwave-assisted reactions, were evaluated in vitro against drug susceptible and multi-drug resistant Mycobacterium tuberculosis, against virulent Mycobacterium bovis, against Mycobacterium ulcerans and against two Mycobacterium avium subspecies. Among the 33 substances that were tested, compound 12, i.e. 4,4'-[1,12-dodecanediyl(oxy)]bisbenzaldehyde, emerged as the most promising hit. Its activity was further confirmed in an intracellular growth inhibition assay of M. tb in murine J774 A.1 macrophages. None of the compounds showed significant cytotoxicity on human C3A hepatocytes in a neutral red dye uptake assay and no genotoxicity or mutagenicity was observed as demonstrated by a VITOTOX (TM) test and confirmed with a comet assay. (C) 2013 Elsevier Masson SAS. All rights reserved.
ANTICANCER FORMULATION
申请人:Chiou Tzyy-Wen
公开号:US20110165201A1
公开(公告)日:2011-07-07
This invention relates to a pharmaceutical formulation containing z-butylidenephthalide and a polymer, e.g., a polyanhydride. Also disclosed is use of this formulation to treat tumor.
US9585864B2
申请人:——
公开号:US9585864B2
公开(公告)日:2017-03-07
Aguilera, C.; Ahmad, S.; Bartulin, J., Molecular Crystals and Liquid Crystals (1969-1991), 1988, vol. 162, p. 277 - 282
作者:Aguilera, C.、Ahmad, S.、Bartulin, J.、Mueller, H. J.